Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.49 |
| ▸ | BRD4 | O60885 | 12/20 | 0.47 |
| ▸ | VRK1 | Q99986 | 3/20 | 0.47 |
| ▸ | VRK2 | Q86Y07 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.47 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.47 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 11/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.45 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.40 |
| ▸ | MAPK7 | Q13164 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12956561 | 0.90 | RPS6KA3 (0.62) | RPS6KA3BRD4VRK1VRK2JAK2 | |
| SCHEMBL12957059 | 0.79 | BRD4 (0.44) | BRD4PLK1BRDTDCLK1MAPK7 | |
| SCHEMBL14101194 | 0.77 | PLK1 (0.50) | RPS6KA3BRD4VRK1PLK1BRDT | |
| SCHEMBL21527053 | 0.77 | RPS6KA3 (0.62) | RPS6KA3BRD4VRK1VRK2JAK2 | |
| SCHEMBL862198 | 0.77 | RPS6KA3 (0.62) | RPS6KA3BRD4VRK1VRK2JAK2 | |
| SCHEMBL13360849 | 0.76 | BRD4 (0.49) | RPS6KA3BRD4VRK1PLK1BRDT | |
| SCHEMBL21527105 | 0.73 | PLK1 (0.59) | RPS6KA3BRD4CSNK1A1RPS6KA2RPS6KA1 | |
| SCHEMBL12956560 | 0.73 | PLK1 (0.69) | RPS6KA3BRD4CSNK1A1RPS6KA2RPS6KA1 | |
| SCHEMBL13814858 | 0.71 | RPS6KA3 (0.46) | RPS6KA3BRD4VRK1VRK2JAK2 | |
| SCHEMBL13104998 | 0.71 | BRD4 (0.72) | RPS6KA3BRD4CSNK1A1RPS6KA2RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807831-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7723517-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-7629460-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-08 | — | — | US | disclosed |
| US-20080319193-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080319192-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080319190-A1 | Antitumor agents; antiproliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-7414053-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | GRAUERT MATTHIAS | 2008-08-14 | — | — | US | disclosed |
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-15 | — | — | US | disclosed |
| US-7332491-B2 | cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent: leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases: arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319192-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | QDPR, DHPS, DHCR7 | RPS6KA3 246/4885BRD4 4130/4885VRK1 2440/4885 |
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | QDPR, DHPS, DHODH | RPS6KA3 554/4885BRD4 4385/4885VRK1 4130/4885 |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | CCNK, CDK1, PLK1 | RPS6KA3 20/4885BRD4 2309/4885VRK1 528/4885 |
| US-20080319193-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | QDPR, DHPS, DHCR7 | RPS6KA3 246/4885BRD4 4130/4885VRK1 2440/4885 |
| US-20080319190-A1 | Antitumor agents; antiproliferative agents | TPD52L2, MKI67, HCCS | RPS6KA3 54/4885BRD4 3570/4885VRK1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.